Skip to main content
About the Institute
  • English
  • Français
  • Español

Breadcrumb

  1. Home
  2. Microbiota 4 - June 2018
  3. Focus on the 2018 GMFH
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
General Medicine

Breadcrumb

  1. Home
  2. Microbiota 4 - June 2018
  3. Focus on the 2018 GMFH
Gastroenterology

Focus on the 2018 GMFH

Drug

Congress review

By Dr. Julien Scanzi
Hepato-gastroenterology, Estaing University Hospital of Clermont-Ferrand and Thiers Hospital Centre, UMR INSERM/ UdA U1107 Neuro-Dol, Clermond-Ferrand Faculties of Medicine, France

Gastroenterology
Gynecology
Pediatrics
General Medicine
  • Our publications
    • News
    • Microbiota Mag
    • Thematic pages
    • Experts' point of view
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • About us
    • International Microbiota Observatory
    • Press room
    • Partnerships
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
  • Useful documents
    • How to talk about
    • Infographics
    • IBS Diagnosis Check List
    • Patients Stories

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • LinkedIn
  • Mail

Sections

Bandeau_Article5_Microbiota_NL-4_FR

About this article

Author

 Julien Scanzi Dr Julien Scanzi
Created 26 August 2021
Updated 29 August 2024

The 7th GMFH summit was held in Rome on March 9-11, 2018. Once again, this year, internationally renowned physicians and researchers met to share the latest scientific advances in the field of microbiota; “a leading field of research”, as stated by Francisco Guarner, Chair of the Scientific Committee and leader of an ambitious programme.

Antibiotics and gut microbiota

The congress began with a Biocodex symposium on the impact of antibiotics on the gut microbiota. Dr. L. Armand- Lefevre recalled that antibiotics cause major alterations in the microbiota, in particular due to both the broad spectrum of antibiotics as well as high intestinal concentrations. In addition, microbiota resilience following antibiotic therapy may be slow and incomplete. In addition to the well-known short-term side effects, such as diarrhoea, taking antibiotics in early childhood is associated with an increased risk of obesity, allergies, and autoimmune diseases, as specified by Dr. A. Mosca.

How can these risks be reduced?

Firstly, by trying to prescribe fewer antibiotics in a better way, moreover, if antibiotic prescription is necessary, by combining them with a probiotic. This is particularly the case for the probiotic, Saccharomyces boulardii, which limits dysbiosis and facilitates microbiota resilience following the discontinuation of antibiotics. Pr. C. Kelly has also shown that S. boulardii decreases the level of primary bile acids and increases that of secondary bile acids, thus reducing the risk of Clostridium difficile infection.

Our mucus needs fibre to defend us

Our fibre consumption has decreased over recent decades, at least in the West, from more than 150 g per day a few generations ago to a dozen grams per day nowadays. This directly impacts the composition of our intestinal mucus. Pr. M. Desai’s Luxembourg team has shown, using a mouse model, that a low-fibre diet results in the intestinal mucus being more strongly degraded by the microbiota via glycoproteins contained in the mucus as an energy substrate. The resulting degraded mucus no longer plays its role against pathogenic bacteria such as Citrobacter rodentium, resulting in lethal colitis in these mice [1].

New biomarkers in colorectal cancer

The potential role of the microbiota in colorectal carcinogenesis is well known. In a metagenomic study conducted in collaboration with Pr. J. Wang’s team in China, Dr. M. Arumugam demonstrated the existence of a“microbial signature” of colorectal cancer (CRC), based on the identification of four biomarkers which were significantly expressed in CRC patients compared to healthy subjects, in geographically different populations (China, Denmark, France, Austria). Of these biomarkers, two bacterial genes of Fusobacterium nucleatum (Fn) and Parvimonas Micra (Pm) were significantly over-expressed in cases of CRC [2]. Another recent study has confirmed the role of Fn as a biomarker of CRC, which significantly increased the sensitivity of immunological screening and made it possible to retrieve 75% of CRC cases which were negative on immunological testing [3].

With this advance in the recognition of a “microbial signature” of CRC, it may be possible to screen asymptomatic individuals for CRC in the near future based on an immunological test for blood in the stools coupled with microbiota analysis.

Impact of the microbiota on the response to immunotherapy

It has been known for a few years that the gut microbiota has an impact on the efficacy of chemotherapies. Recently, studies have also shown that the microbiota plays a major role in the response to immunotherapy. Based on a study of 26 metastatic melanoma patients, Pr. F. Carbonnel’s team showed that the type of microbiota is correlated with the response to ipilimumab (anti-CTLA-4). Patients with a microbiota rich in Faecalibacterium and other Firmicutes demonstrated a high response rate to ipilimumab and a significantly increased survival rate. The occurrence of ipilimumab-induced colitis was also more common in this group [4]. Similarly, another recent study based on 112 metastatic melanoma patients has shown that their responses to anti-PD-1 varied, and their microbiota, alpha-diversity, and relative abundance in Ruminococcaceae (a family whose main member is Faecalibacterium) were the main predictive factors for response [5].

Focusing on faecal microbiota transplantation

As was the case last year, faecal microbiota transplantation (FMT) was the subject of a workshop and was often referred to in the various presentations. Drs. G. Ianiro and Z. Kassam recalled the very promising results of FMT for ulcerative colitis (two positive randomised controlled trials and one trial which showed a positive trend with FMT although significance was not reached), metabolic syndrome, hepatic encephalopathy, irritable bowel syndrome, and digestive GVH (graft-versus-host) allograft. Apart from recurrent Clostridium difficile infection, repeated FMT appears to be essential for “engraftment” and treatment efficacy. Administration in capsules seems to be the future for this technique but questions remain, in particular around intake dose and frequency, since these parameters are also likely to vary according to indication. Access to FMT is increasingly facilitated by the emergence of “stool banks”, in particular, in countries in which microbiota transplants have been assigned the status of organ/tissue rather than medicine. For example, in the United States, 98% of the population is within a two-hour drive of a centre practicing FMT. Thus, this practice has been widely used in recent years, but remains to be standardised and possibly adapted to patients according to their disease and microbiota.

 

Akkermansia Muciniphila: a new-generation probiotic?

Discovered in 2004, A. muciniphila is a bacterium that prevails in the mucus. It degrades mucin, stimulates butyrate production, and produces a pili-like protein, Amuc1100, that appears to play an important role in the immune response and barrier function of the intestinal mucus. It appears to have beneficial properties since its presence is inversely correlated to obesity, metabolic syndrome, and some cardiovascular diseases [6, 7]. In mice, its administration has beneficial effects on metabolic syndrome, and the first clinical data in humans should soon be available.

Sources

1 Desai MS, Seekatz AM, Koropatkin NM, et al. A Dietary Fiber-Deprived Gut Microbiota Degrades the Colonic Mucus Barrier and Enhances Pathogen Susceptibility. Cell. 2016;167(5):1339-1353.e21.

2 Yu J, Feng Q, Wong SH, et al. Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. Gut. 2017;66(1):70-78.

3 Wong SH, Kwong TNY, Chow TC, et al. Quantitation of faecal Fusobacterium improves faecal immunochemical test in detecting advanced colorectal neoplasia. Gut. 2017;66(8):1441-1448.

4 Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2017;28(6):1368-1379.

5 Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97-103.

6 Plovier H, Everard A, Druart C, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017;23(1):107-113.

7 Ottman N, Reunanen J, Meijerink M, et al. Pili-like proteins of Akkermansia muciniphila modulate host immune responses and gut barrier function. PLoS One. 2017;12(3):e0173004. 

Tags
Gastroenterology Pediatrics Cancer GMFH Microbiome Flora
    Focus
    Microbiota 4 - June 2018
    • Overview
      • Targeting the gut microbiota to combat allergies
    • Commented articles
      • The role of Fusobacterium in colorectal cancer
      • Adaptation of commensal Escherichia coli in the intestinal tract of young children with cystic fibrosis
    • Congress review
      • 2017 UEG WEEK
      • Focus on the 2018 GMFH
    • Press review
      • Intestinal microbiota modulates tumour response in cancer patients
      • Maternal obesity during pregnancy and delivery mode
    Created 26 August 2021
    Updated 29 August 2024

    About this article

    To know more about this topic.

    Main topic

    Drug

    Content type

    Congress review

    Author

     Julien Scanzi Dr Julien Scanzi
    2017 UEG WEEK
    Intestinal microbiota modulates tumour response in cancer patients
    Focus

    Microbiota 4 - June 2018

    Overview

    Targeting the gut microbiota to combat allergies

    Commented articles

    The role of Fusobacterium in colorectal cancer Adaptation of commensal Escherichia coli in the intestinal tract of young children with cystic fibrosis

    Congress review

    2017 UEG WEEK Focus on the 2018 GMFH

    Press review

    Intestinal microbiota modulates tumour response in cancer patients Maternal obesity during pregnancy and delivery mode

    Continue reading

    News

    Infographics to share with your patients!

    Download original and engaging graphic materials to explain to your patients the essential role of th...

    Find out more
    Actu PRO : Malnutrition : agir sur le microbiote pour améliorer la croissance, un prototype à l’essai
    08.07.2021

    Malnutrition: acting on the microbiota in order to improve growth, a trial prototype

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    07.02.2025

    Your functional dyspepsia diagnosis check list

    Read the article
    17.04.2025

    Sensitivity to the additive E466: the role of the microbiota

    Read the article
    Photo HCPs: Clinical context over quick fix: the fresh consensus on microbiome testing
    11.04.2025

    Clinical context over quick fix: the fresh consensus on microbiome testing

    Read the article
    Actu PRO : Alcoolisme : expliquer les troubles sociaux grâce au microbiote
    27.01.2021

    Alcoholism: explaining social disorders thanks to the microbiota

    Read the article

    Association between fungal dysbiosis and environment

    The fungal portion of the gut microbiota (or mycobiota) has been much less studied than the bacterial...

    Find out more
    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine
    • English
    • Français
    • Español

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    14.05.2025

    Towards worldwide redefinition of healthy vaginal microbiota

    Read the article
    07.05.2025

    The microbial-metabolic nexus in colon cancer

    Read the article
    02.05.2025

    A new lens on chlamydia: beyond behavior, into the microbiome

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive “Microbiota Digest” and "Microbiota Mag" to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic pages
      • Experts' point of view
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • About us
      • International Microbiota Observatory
      • Press room
      • Partnerships
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
    • Useful documents
      • How to talk about
      • Infographics
      • IBS Diagnosis Check List
      • Patients Stories

      Join the microbiota community

      • Facebook
      • Twitter
      • LinkedIn
      • YouTube
      • Instagram
      • Bluesky

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    General Medicine

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • LinkedIn
    • YouTube
    • Instagram
    • Bluesky

    © 2025 Biocodex. All rights reserved.

    • Legal notice
    • GTU
    • Data protection policy
    • Sitemap
    • Cookies settings
    • Digital accessibility : partially compliant
    Biocodex logo